{"prompt": "['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', '6.2.1.1 Definitions', '6.2.1.1.1', 'Adverse Event', 'An adverse event (AE) is defined in the International Conference on Harmonization (ICH)', 'Guideline for Good Clinical Practice as \"any untoward medical occurrence in a patient or', 'clinical investigation subject administered a pharmaceutical product and which does not', 'necessarily have a causal relationship with this treatment.\" (ICH E6: section 1.2).', 'An adverse event can therefore be any unfavourable and unintended sign (including an', 'abnormal laboratory finding, for example), symptom, or disease (including a worsening in the', 'character, frequency, of severity of a pre-existing illness) temporally associated with the use', 'of a medicinal (investigational) product, whether or not considered related to the medicinal', '(investigational) product.', '6.2.1.1.2', 'Adverse Drug Reaction', 'Adverse drug reactions (ADR) are all noxious and unintended responses to a medicinal', 'product related to any dose administered\" (European Directive 2001/20/EC).', 'The phrase \"responses to a medicinal product\" means that a causal relationship between a', 'medicinal product and an adverse event is at least a reasonable possibility, i.e. the relationship', 'cannot be ruled out.', 'A serious ADR (SADR) is an ADR that meets the definition of serious (provided below).', '6.2.1.1.3', 'Serious Adverse Event', 'A serious adverse event (SAE) is defined as any untoward medical occurrence (adverse event)', 'that at any dose', 'results in death', 'is life-threatening (subject was at immediate risk of death at the time of the event)', 'requires in-patient hospitalization or prolongation of existing hospitalization', 'results in persistent or significant disability/incapacity', 'is a congenital anomaly/birth defect', 'is another significant medical condition/event', 'A hospitalization meeting the regulatory definition for \"serious\" is any inpatient hospital', 'admission that includes a minimum of an overnight stay in a health care facility. Any adverse', 'event that does not meet one of the definitions of serious i.e. important medical events that', 'may not be immediately life-threatening or result in death or hospitalization but may jeopardize', 'the patient or may require interventions to prevent one of the other outcomes listed above (e.g.', 'emergency room visit, outpatient surgery, or requires urgent investigation) may be considered', 'by the investigator to meet the \"other significant medical condition\" criterion for classification', 'as', 'a serious adverse event. Examples include allergic bronchospasm, convulsions, and blood', 'dyscrasias.', 'Confidential', 'Page 52 of 79']['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'Hospitalization for performing of protocol-required procedures or administration of study', 'treatment or hospitalizations for procedures planned prior to study start and elective', 'hospitalizations are not classified as an SAE, however any AE that occurs during this', 'hospitalization and meets any of the above mentioned criteria of seriousness needs to be', 'reported as SAE.', 'Any second primary malignancy occurring in a patient during or after study treatment within', 'the safety reporting period will be assessed as important medical event and thus has to be', 'reported as SAE.', 'Progression of the underlying malignant disease and symptoms caused by progression of the', 'underlying tumor disease need not to be reported as SAE in this protocol, unless progression', 'or symptoms of progression are assessed as causally related to study medication.', '6.2.1.1.4 Unexpected Adverse Event / Suspected Unexpacted Serious Adverse', 'Reaction', 'An unexpected adverse event is any adverse drug event, the specificity or severity of which is', 'not consistent with the current version of the respective SmPCs of routine chemotherapy', 'medications. Also, reports which add significant information on specificity or severity of a', 'known, already documented adverse event constitute unexpected adverse events. An event', 'more specific or more severe than described in the current version of the respective SmPCs', 'of routine chemotherapy medications would be considered \"unexpected\".', 'A suspected unexpected serious adverse reaction (SUSAR) is a serious adverse reaction, the', 'nature or severity of which is not consistent with the applicable safety reference document', '(SmPC). All suspected adverse reactions related to study medication which occur in this trial', 'and are both unexpected and serious (SUSARs) are subject to expedited reporting.', 'SAEs which are \"serious\", \"related\" and \"unexpected\" meet the criteria for SUSAR.', 'In case of SUSARs a CIOMS report is completed and forwarded to the competent authorities,', 'all participating investigators and the Sponsor. According to \u00a7 13 of the GCP guideline SUSAR', 'reporting occurs immediately, but no later than 15 calendar days. Reporting of life-threatening', 'or fatal SUSARs occurs immediately, but no later than 7 calendar days.', '6.2.1.2 Adverse Events Reporting', \"All adverse events are documented by the participating site in the patient's medical records\", 'and the eCRF. AEs are assessed from date of first study treatment until 4 weeks after the last', 'dose of study therapy at every visit. For Arm B in which patients are not being actively treated,', 'adverse events should be queried at every visit (planned and unplanned) during the first 7', 'months from randomization, but at least twice (i.e. at the 3 and 6 months visit). Thereafter,', 'adverse events should be queried every three months for both groups by an unbiased open', 'question for up to two years after randomization.', 'In addition to the documentation in the eCRF, all SAEs are reported by the site immediately,', 'without undue delay, but not later than 24 hours after obtaining knowledge to the CRO by fax', 'or email.', 'Confidential', 'Page 53 of 79']\n\n###\n\n", "completion": "END"}